News Release

Factor found to balance medically useful stem cell qualities

Peer-Reviewed Publication

The Mount Sinai Hospital / Mount Sinai School of Medicine

A key protein controls stem cell properties that could make them more useful in regenerative medicine, according to a study led by Mount Sinai researchers and published online today in the journal Cell Stem Cell.

Each of us develops from an unspecialized single cell into hundreds of different specific cell types. Stem cells multiply (proliferate) and mature (differentiate) in the womb to become muscle, bone, nerves, etc. To make stem cells the basis for safe medical treatments, however, the field would need the ability to tightly control stem cell pluripotency, the ability to become many cell types, and self-renewal or immortality, the ability to keep dividing and multiplying over time in constant turnover.

This elusive stability must be achieved before stem cell supplies can be kept on hand until it is time to turn them into replacements for say misshapen red blood cells seen in sickle cell anemia or abnormal white blood cells causing leukemia. Also limiting the use of therapeutic stem cells to date, self-renewal, a quality so vital to a fast-growing fetus, can also be a source of cancer risk when haphazard, unlimited cell multiplication results in the abnormal tissue growth seen in tumors.

In the current study, Mount Sinai researchers found that the protein called "zinc finger protein 217" (ZFP217) regulates the actions of genes that maintain a balance between stem cell self-renewal and differentiation. The study results were found using mouse embryonic stem cells, which are good cell models for the study of processes seen in human stem cells.

"The hope is that ZPF217 could be used to maintain supplies of therapeutic stem cells," said lead study author Martin Walsh, PhD, Associate Professor of Pediatrics, Structural and Chemical Biology, and Genetics and Genomic Sciences of the Icahn School of Medicine at Mount Sinai. "At the same time, as the human ZNF217 is associated with poor survival in a variety of cancers, understanding how this protein operates in physiological conditions may help to predict cancer risk, achieve earlier diagnosis and provide novel therapeutic approaches."

The study results build on genetic and epigenetic basics, including that the blueprint for the human body is encoded in genes that direct the building of one or more proteins. Gene expression is the process where information stored as DNA is converted (transcribed) by enzymes into related molecules called RNAs, and then into proteins that make up the body's structures and signals.

A transcriptome is the set of all RNA molecules transcribed in each cell type, and a readout on which genes are turned in that cell at the time. DNA is transcribed into messenger RNA (mRNA) that carries the code to ribosomes, the molecular machines that build proteins by reading the mRNA instructions. At several points in the process of turning on genes, transcribing them into RNAs, and then translating them into proteins, chemical changes may occur that either encourage or interfere with that gene expression.

This is the science of epigenetics, in which chemical changes to genetic material turn genes on or off without changing the order of the DNA code inherited from your parents. Methylation, the chemical attachment at a certain point on the DNA chain of a methyl group (one carbon atom bonded to three hydrogen atoms), is a common type of epigenetic, regulatory change that can "silence" a gene.

While many epigenetic mechanisms regulate genetic function at the level of DNA, an emerging science looks at regulation through chemical changes to RNAs in yet another level of regulatory finesse.

N6-Methyladenosine (m6A) is the most commonly occurring RNA modification in human cells, influencing the stability and its ability to carry genetic messages. In the current study, ZFP217 was found to regulate m6A deposition on to mRNAs created by stem cell pluripotency genes by attaching to another enzyme, m6A methyltransferase-like 3 (METTL3), and rendering it inactive. This prevents methylations that would otherwise cause the stem cells to differentiate, putting an end to their self-renewal and pluripotency.

At the same time, the study results provide further argument for notion that m6A methylation, partly controlled by ZFP217 signaling, is relevant in human cancers. Overexpression of ZNF217 provides an advantage to tumor cells by allowing cells to infinitely proliferate and turning down pathways that typically tell cells to mature into functional cells (bone, blood, skin cells).

The research team also found that ZFP217 turns on the genes important for stemness, including Nanog and Sox2. ZFP217 expression may in turn be influenced by these same factors in the kind of feedback loop seen in complex genetic regulation.

Since 2006, researchers have been able of take differentiated specialized cells, like skin cells, and transform them into induced pluripotent stem cells or iPSCs. Such iPSCs are genetically specific to that patient. This offers the promise of creating personalized, therapeutic stem cells. Nanog and Sox2 are among the enzymes used by researchers to generate iPSCs, therefore ZFP217 may represent another tool needed to achieve tight control over cell reprogramming.

###

Along with Dr. Walsh, corresponding author was Francesca Aguilo, and other authors were Ana Sancho, Serena Di Cecilia, Chih-Hung Chen, Madhumitha Rengasamy, Blanca Andino, Farid Jahouh and Rong Wang in the Department of Structural and Chemical Biology, Icahn School of Medicine at Mount Sinai. Several of these researchers are also faculty in the Departments of Pediatrics and in the Department Genetics and Genomic Sciences at the Icahn School of Medicine. Also making important contributions for Mount Sinai were Fan Zhang and Weijia Zhang in the Department of Medicine, Division of Nephrology, Bioinformatics Laboratory; and Miguel Fidalgo, Dung-Fang Lee, and Jianlong Wang of the Department of Developmental and Regenerative Biology and The Black Family Stem Cell Institute.

In addition, Ajay Vashisht and James Wohlschlegel in the Department of Biological Chemistry and the Institute of Genomics and Proteomics, University of California, Los Angeles, Angel Roman pf the Instituto Cajal - Consejo Superior de Investigaciones Científicas, in Madrid, Spain, and Sheryl Krig in the Department of Biochemistry and Molecular Medicine, UC Davis School of Medicine, Sacramento, were study authors.

The study was funded by awards from the Ellison Medical Foundation Senior Scholar Award in Aging (AG-SS-2482-10), National Institutes of Health (HL103967, CA154809, DA 028776, and GM089778) and the Empire State Stem Cell Fund through New York State Department of Health (NYSTEM C028103 and C028121). Dr. Aguilo received support from the Catalan Agency for Administration of University and Research (AGAUR) as a fellow.

About the Mount Sinai Health System

The Mount Sinai Health System is an integrated health system committed to providing distinguished care, conducting transformative research, and advancing biomedical education. Structured around seven hospital campuses and a single medical school, the Health System has an extensive ambulatory network and a range of inpatient and outpatient services--from community-based facilities to tertiary and quaternary care.

The System includes approximately 6,100 primary and specialty care physicians; 12 joint-venture ambulatory surgery centers; more than 140 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers. Physicians are affiliated with the renowned Icahn School of Medicine at Mount Sinai, which is ranked among the highest in the nation in National Institutes of Health funding per investigator. The Mount Sinai Hospital is nationally ranked as one of the top 25 hospitals in 8 specialties in the 2014-2015 "Best Hospitals" issue of U.S. News & World Report. Mount Sinai's Kravis Children's Hospital also is ranked in seven out of ten pediatric specialties by U.S. News & World Report. The New York Eye and Ear Infirmary of Mount Sinai is ranked nationally, while Mount Sinai Beth Israel, Mount Sinai St. Luke's, and Mount Sinai Roosevelt are ranked regionally.

For more information, visit http://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.